BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 29809272)

  • 1. [Osteonecrosis of the jaws (ONJ) associated to antiresorptive treatment].
    Larsson Wexell C; Kjellman A; Akre O
    Lakartidningen; 2018 May; 115():. PubMed ID: 29809272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E; Bamias A
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
    J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
    Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?
    Colella A; Yu E; Sambrook P; Hughes T; Goss A
    J Oral Maxillofac Surg; 2023 Feb; 81(2):232-237. PubMed ID: 36442534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Osteonecrosis of the jaw].
    Drozdzowska B
    Endokrynol Pol; 2011; 62 Suppl 3():4-9. PubMed ID: 22161980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bisphosphonate and osteonecrosis of the jaw.].
    Taguchi A
    Clin Calcium; 2017; 27(2):225-231. PubMed ID: 28123124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws.
    Kagami H; Inoue M; Kobayashi A; Taguchi A; Li X; Yoshizawa M
    Oral Dis; 2018 Mar; 24(1-2):52-56. PubMed ID: 29480637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of Osteonecrosis of the Jaws.
    Aghaloo T; Hazboun R; Tetradis S
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):489-96. PubMed ID: 26412796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw.
    Goodday RH
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):527-36. PubMed ID: 26293331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
    J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
    Takaoka K; Kishimoto H
    Nihon Yakurigaku Zasshi; 2019; 153(1):22-27. PubMed ID: 30643088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preserving the oral health of patients on antiresorptive drugs].
    Tilotta F; Folliguet M; Radoï L
    Rev Prat; 2023 Apr; 73(4):421-429. PubMed ID: 37289162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiresorptives and osteonecrosis of the jaw.
    Yamashita J; McCauley LK
    J Evid Based Dent Pract; 2012 Sep; 12(3 Suppl):233-47. PubMed ID: 23040351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiresorptive-Type and Discontinuation-Timing Affect ONJ Burden.
    Hadaya D; Soundia A; Gkouveris I; Bezouglaia O; Dry SM; Pirih FQ; Aghaloo TL; Tetradis S
    J Dent Res; 2021 Jul; 100(7):746-753. PubMed ID: 33478337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.